In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

Merck recently declared a Q4 dividend of $0.81 per share while also securing Health Canada's nod for KEYTRUDA® in cervical ...